Compounds > valsartan
Page last updated: 2024-08-24

valsartan and Liver Cirrhosis

valsartan has been researched along with Liver Cirrhosis in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (22.22)29.6817
2010's6 (66.67)24.3611
2020's1 (11.11)2.80

Authors

AuthorsStudies
Chang, CC; Chuang, CL; Hou, MC; Hsu, SJ; Huang, HC; Huang, YH; Lee, FY; Pun, CK1
El-Hadidy, WF; El-Khatib, AS; El-Mezayen, NS; El-Refaie, WM; Khattab, MM; Shalaby, TI1
Alves, C; Carballo, S; Darbellay, P; Lebowitz, D; Moret, M; Sabeh, N1
Chang, YK; Choi, DE; Choi, H; Jeong, JY; Lee, KW; Na, KR1
Huo, LJ; Liu, Y; Zhang, SJ1
Chiu, YH; Hsu, BG; Ke, CY; Lee, CJ; Lin, NT; Subeq, YM1
Aksak, S; Albayrak, A; Albayrak, F; Gundogdu, C; Halici, Z; Karakus, E; Kiki, I; Ozturk, B; Polat, B; Sipal, S1
Arslan, A; Cihangiroğlu, M; Demir, A; Yalniz, M1
Andronescu, D; Bengus, A; Dragomir, P; Fierbinteanu-Braticevici, C; Negreanu, L; Tribus, L; Usvat, R1

Trials

2 trial(s) available for valsartan and Liver Cirrhosis

ArticleYear
[Clinical evaluation of valsartan on portal hypertension in patients with hepatic cirrhosis].
    Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2010, Volume: 18, Issue:8

    Topics: Female; Humans; Hypertension, Portal; Liver Cirrhosis; Male; Tetrazoles; Valine; Valsartan

2010
The effect of valsartan, an angiotensin II receptor antagonist, on portal and systemic hemodynamics and on renal function in liver cirrhosis.
    Journal of gastrointestinal and liver diseases : JGLD, 2006, Volume: 15, Issue:4

    Topics: Adult; Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Creatinine; Female; Hemodynamics; Humans; Hypertension, Portal; Kidney; Liver Cirrhosis; Male; Metanephrine; Middle Aged; Natriuresis; Portal System; Renin; Romania; Single-Blind Method; Sodium; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan

2006

Other Studies

7 other study(ies) available for valsartan and Liver Cirrhosis

ArticleYear
Dual angiotensin receptor and neprilysin inhibitor reduced portal pressure through peripheral vasodilatation and decreasing systemic arterial pressure in cirrhotic rats.
    Journal of the Chinese Medical Association : JCMA, 2023, 09-01, Volume: 86, Issue:9

    Topics: Animals; Antihypertensive Agents; Antiviral Agents; Arterial Pressure; Hypertension, Portal; Liver Cirrhosis; Male; Neprilysin; Portal Pressure; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Valsartan; Vasodilation

2023
Oral vitamin-A-coupled valsartan nanomedicine: High hepatic stellate cell receptors accessibility and prolonged enterohepatic residence.
    Journal of controlled release : official journal of the Controlled Release Society, 2018, 08-10, Volume: 283

    Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Hepatic Stellate Cells; Intestines; Liposomes; Liver; Liver Cirrhosis; Male; Nanomedicine; PPAR gamma; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Valsartan; Vitamin A; Vitamins

2018
[Internal medicine in the hospital setting].
    Revue medicale suisse, 2015, Jan-21, Volume: 11, Issue:458

    Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Asymptomatic Diseases; Atrial Fibrillation; Biphenyl Compounds; Carotid Stenosis; Colchicine; Diuretics; Drug Combinations; Heart Failure; Hospitals; Humans; Internal Medicine; Liver Cirrhosis; Narcotics; Neprilysin; Pericarditis; Peritonitis; Pulmonary Disease, Chronic Obstructive; Respiratory Therapy; Spironolactone; Stroke; Tetrazoles; Valsartan

2015
Co-inhibition of Angiotensin II Receptor and Endothelin-1 Attenuates Renal Injury in Unilateral Ureteral Obstructed Mice.
    Kidney & blood pressure research, 2016, Volume: 41, Issue:4

    Topics: Acute Kidney Injury; Animals; Antihypertensive Agents; Bosentan; Drug Synergism; Endothelin-1; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Receptors, Angiotensin; Sulfonamides; Ureteral Obstruction; Valsartan

2016
Valsartan decreases TGF-β1 production and protects against chlorhexidine digluconate-induced liver peritoneal fibrosis in rats.
    Cytokine, 2011, Volume: 53, Issue:2

    Topics: Animals; Blood Pressure; Chlorhexidine; Glucose; Heart Rate; Immunohistochemistry; Liver Cirrhosis; Male; Peritoneal Dialysis; Peritoneal Fibrosis; Peritoneum; Protective Agents; Rats; Rats, Sprague-Dawley; Staining and Labeling; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan

2011
Comparative study of three angiotensin II type 1 receptor antagonists in preventing liver fibrosis in diabetic rats: stereology, histopathology, and electron microscopy.
    Journal of molecular histology, 2012, Volume: 43, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Experimental; Imidazoles; Liver Cirrhosis; Losartan; Male; Microscopy, Electron; Rats; Tetrazoles; Valine; Valsartan

2012
Short term effects of valsartan on portal blood flow in cirrhotic patients.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2003, Volume: 14, Issue:1

    Topics: Adolescent; Adult; Aged; Biopsy, Needle; Blood Flow Velocity; Cohort Studies; Female; Follow-Up Studies; Humans; Hypertension, Portal; Liver Circulation; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Portal System; Prospective Studies; Risk Assessment; Severity of Illness Index; Tetrazoles; Treatment Outcome; Ultrasonography, Doppler; Valine; Valsartan

2003